Next Article in Journal
Phenolic Extracts from Acacia mangium Bark and Their Antioxidant Activities
Previous Article in Journal
Neuroprotective Herbs and Foods from Different Traditional Medicines and Diets
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 15
Issue 5
10.3390/molecules15053556
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Characterization of Aromatase Binding Agents from the Dichloromethane Extract of Corydalis yanhusuo Using Ultrafiltration and Liquid Chromatography Tandem Mass Spectrometry

by
Jing Shi
1,,
Xiaoyu Zhang
2,,
Zhongjun Ma
2,*,
Min Zhang
2 and
Fang Sun
2
1
1-Department of Pharmacy, Zhejiang Medical College, No.481 Binwen Rd., Hangzhou 310053, China
2
2-School of Pharmaceutical Sciences, Zhejiang University, Zijingang Campus, No.388 Yuhangtang Rd., Hangzhou 310058, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2010, 15(5), 3556-3566; https://doi.org/10.3390/molecules15053556
Submission received: 24 March 2010 / Revised: 5 May 2010 / Accepted: 11 May 2010 / Published: 14 May 2010
Browse Figures
Versions Notes

Abstract

:
Aromatase represents an important target for the treatment of hormone-dependent breast cancer. In the present study, nine alkaloids from the dichloromethane extract of Corydalis yanhusuo were identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) and tested for their aromatase binding activities using an ultrafiltration LC-MS method by investigating the differences of peak areas of compounds before and after incubations with aromatase. It was demonstrated that the quaternary protoberberine alkaloids and the tertiary protoberberine alkaloids exhibited potent aromatase binding activities. The quaternary ammonium group and the methyl group at C-13 position of tertiary protoberberine alkaloids might be necessary for the activity. The findings should provide guidance for the discovery of potential aromatase inhibitors from natural products.

Graphical Abstract

1. Introduction

Breast cancer is a worldwide health problem and remains one of the leading causes of death among women. Approximately one-third of all breast cancers are hormone (estrogen) dependent. Though a variety of different treatment options are currently available, the incidence and mortality of breast cancer remain extremely high up to the present. It was widely recognized that estrogens and estrogen receptors (ERs) play key roles in the development and progression of hormone-dependent breast cancer [1]. With regard to the mechanisms involved in above process, two general strategies have been developed for the prevention or therapy of hormone-dependent breast cancer [2]. The first strategy is to introduce anti-estrogen agents such as tamoxifen to inhibit the binding of estrogens to ERs [3]. The second approach is to use aromatase inhibitors (AIs) to decrease the circulating levels of estrogens by blocking the biosynthesis of estrogens from androgens [4].
Aromatase, encoded by the CYP19 gene, is expressed in various tissues including ovary, placenta, bone, brain, liver, muscle, subcutaneous fat and normal breast tissues [5]. It is a key enzyme involved in the estrogen biosynthesis by converting androstenedione to estrone, or testosterone to estradiol. Deprivation of estrogens by AIs has been proved one of the most effective endocrine treatment strategies of breast cancer in previous study [6,7]. Until now, it has been demonstrated that some synthetic AIs such as anastrozole, letrozole and exemestane show improved efficacies against breast cancer and could reduce the side effects of tamoxifen [8,9,10,11]. However, they may also cause some other side effects, such as osteoporosis and alterations in lipid profiles [12,13].
Natural products have long been considered as an important source of chemopreventive and chemotherapeutic agents. The large number of bioactive natural products will offer unprecedented opportunities for finding novel small molecules possessing both efficacy and safety targeting the aromatase. More and more natural products such as flavonoids [14], coumarins [15], sesquiterpenes [16] and polyphenols [17] have been proved to possess potent aromatase inhibiting activities. Corydalis yanhusuo is a well-known traditional Chinese medicine (TCM) and has been used to promote blood circulation, reinforce vital energy and alleviate various kinds of pain for a long history [18,19]. The mainly bioactive chemical constituents in C. yanhusuo are tertiary and quaternary isoquinoline alkaloids [20,21,22]. Considering the previous studies indicating that C. yanhusuo could effectively inhibit human breast cancer cells [23] and alkaloids possessed aromatase inhibiting activities [24], in this study, we established an ultrafiltration liquid chromatography tandem mass spectrometry (LC-MS) method to screen the potential aromatase binding agents from the dichloromethane extract of C. yanhusuo.

2. Results and Discussion

2.1. HPLC-DAD-MS/MS analysis of the dichloromethane extract of C. yanhusuo

The HPLC-DAD (Diode Array Detector) chromatogram and the total ion current (TIC) chromatogram of the dichloromethane extract of C. yanhusuo are shown in Figure 1.
Molecules 15 03556 g001 550
Figure 1. The HPLC-DAD chromatogram (a) and the total ion current (TIC) chromatogram (b) of the dichloromethane extract of C. yanhusuo.
Figure 1. The HPLC-DAD chromatogram (a) and the total ion current (TIC) chromatogram (b) of the dichloromethane extract of C. yanhusuo.
Molecules 15 03556 g001
The positive ion mode of electrospray ionization (ESI) was selected for all subsequent MS analysis of the constituents in the dichloromethane extract of C. yanhusuo because the protonated molecules of these compounds in positive ion mode were well responsed. As shown in Figure 1, under the optimized HPLC-DAD-MS/MS condition, twelve constituents in C. yanhusuo were well separated. Then we isolated nine reference compounds from the dichloromethane extract of C. yanhusuo (Figure 2).
Molecules 15 03556 g002 550
Figure 2. Chemical structures of isolated compounds from the dichloromethane extract of C. yanhusuo.
Figure 2. Chemical structures of isolated compounds from the dichloromethane extract of C. yanhusuo.
Molecules 15 03556 g002
Their structures were elucidated by NMR spectroscopic analysis and comparison with the literature data [25,26,27,28]. The 1H- and 13C-NMR spectra of each reference compound was shown in supplementary material. By comparing the MS2 fragments and the ultraviolet (UV) absorptions of the peaks in the dichloromethane extract of C. yanhusuo with those of the isolated reference compounds, we identified eight peaks in the HPLC-DAD chromatogram in Figure a. One of the isolated reference compounds, berberine, was not observed in the HPLC-DAD chromatogram and the TIC chromatogram of the dichloromethane extract of C. yanhusuo because of its low content. The data of retention time, MS2 fragment and the special UV wavelength of the constituents detected in the dichloromethane extract of C. yanhusuo were listed in Table 1.
Table
Table 1. Peak assignments for analysis of the dichloromethane extract of C. yanhusuo.
Table 1. Peak assignments for analysis of the dichloromethane extract of C. yanhusuo.
No.tRIdentification[M+H]+ m/zMS2 m/zUV λmax (nm)
19.72unknown356326,192209, 229, 276
212.11tetrahydrocolumbamine342178208, 229, 282
315.45protopine354320,206,188209, 237, 289
416.52allocryptopine370352,324,320,188208, 225, 284
518.59tetrahydropalmatine356320,192209, 229, 282
619.29unknown356325,279225, 281, 302
726.61unknown352337,279229, 266, 336
828.09palmatine352336,294,278228, 273, 344
929.57corydaline370352,336,294,192208, 229, 282
1036.02dehydrocorydaline366336,292229, 272, 335
1156.09unknown366336,308215
1257.83dehydroglaucine354336,292233, 258, 320
We noticed that many constituents in the dichloromethane extract of C. yanhusuo had the same molecular weights, but different retention times. Peaks 1, 5 and 6 obtained the same ions at m/z 356 and their retention times were 9.72, 18.59 and 19.29 min respectively. We identified peak 5 as tetrahydropalmatine, according to the same MS2 fragment and UV spectrum with the isolated reference compound. However, when came to peak 1 and 6, since no reference compounds were available for comparison, it was difficult to characterize their accurate structures using only the MS2 fragments and the UV spectra. The same situation occurred in the identification of peaks 7 and 8, which had the same ions at m/z 352. Peaks 8 and 12 were identified as palmatine and dehydroglaucine by comparing the MS2 fragments and the UV spectra with those of the isolated reference compounds.

2.2. Ultrafiltration LC-MS screening for aromatase binding agents from the dichloromethane extract of C. yanhusuo

In previous studies, ultrafiltration combined with LC-MS could be used to investigate the ligands to some macromolecular targets, such as adenosine deaminase [29,30], cyclooxygenase-2 [31] and estrogen receptors [32,33]. Herein, we used this screening method to discover aromatase binding agents from the dichloromethane extract of C. yanhusuo. The schematic of the ultrafiltration LC-MS screening method is shown in Figure 3a. First, compounds in the extract were allowed to bind to aromatase, and then ultrafiltration was used to separate the aromatase-ligand conjugates from the compounds that did not bind to aromatase. Finally, LC-MS was employed to analyze the ultrafiltrate in which the peak area of aromatase binding agent would decrease or disappear compared with that of the control, and thus specific aromatase binding agents could be identified clearly. To validate the assay, we first chose naringenin as the positive control, which had been proved to possess aromatase inhibiting activity in previous studies [34,35], the result is shown in Figure 3b.
Molecules 15 03556 g003 550
Figure 3. Ultrafiltration LC-MS screening for the aromatase binding activity of naringenin. (A) Schematic of the ultrafiltration LC-MS screening method. (B) HPLC chromatograms before (blue) and after (red) incubation of naringenin with aromatase.
Figure 3. Ultrafiltration LC-MS screening for the aromatase binding activity of naringenin. (A) Schematic of the ultrafiltration LC-MS screening method. (B) HPLC chromatograms before (blue) and after (red) incubation of naringenin with aromatase.
Molecules 15 03556 g003
Subsequently, the dichloromethane extract of C. yanhusuo was analyzed by the ultrafiltration LC-MS screening method to discover the potential aromatase binding agents. As shown in Figure 4, after incubation of the dichloromethane extract of C. yanhusuo with aromatase, the area of peaks 2, 5, 6, 8 and 9 decreased by 21.0%, 22.5%, 41.0%, 45.8% and 74.2% respectively.
Molecules 15 03556 g004 550
Figure 4. HPLC chromatograms before (black) and after (red) incubation of the dichloromethane extract of C. yanhusuo with aromatase.
Figure 4. HPLC chromatograms before (black) and after (red) incubation of the dichloromethane extract of C. yanhusuo with aromatase.
Molecules 15 03556 g004
The data of the peak areas that compounds before and after incubating with aromatase is listed in Table 2. Except for peak 6 that could not be identified due to the lack of reference compound, the other peaks 2, 5, 8 and 9 represented tetrahydrocolumbamine, tetrahydropalmatine, palmatine and corydaline respectively. Then, nine isolated reference alkaloids were mixed and their aromatase binding activities tested using the same screening method as described above to validate our results. As shown in Figure 5, after incubation of the mixed reference compounds with aromatase, the area of peaks 2, 5, 8, 9 and 10 decreased by 7.0%, 18.2%, 23.6%, 36.5% and 18.5% respectively (Table 2). In addition, the area of the peak at 17.08 min, corresponding to the isolated alkaloid berberine which could not be observed in Figure 1 and Figure 4, also decreased by 27.8%. The results of the mixed sample were coincident with those of the extract except for peak 10, which was unchanged in the extract but decreased in the mixed sample. This could be explained that the relative content of dehydrocorydaline (peak 10) in the dichloromethane extract of C. yanhusuo was much higher than that in the mixed sample, since the binding site of aromatase was limited, the few binding dehydrocorydaline could not result in the significant difference between incubation with aromatase and the control group.
Molecules 15 03556 g005 550
Figure 5. HPLC chromatograms before (black) and after (red) incubation of the mixed reference compounds with aromatase.
Figure 5. HPLC chromatograms before (black) and after (red) incubation of the mixed reference compounds with aromatase.
Molecules 15 03556 g005
Table
Table 2. Peak areas of compounds before and after incubating with aromatse.
Table 2. Peak areas of compounds before and after incubating with aromatse.
Peak no.Dichloromethane extractMixed reference compounds
Before (mAU·min)After (mAU·min)Decrease (%)Before (mAU·min)After (mAU·min)Decrease (%)
2770.103608.38121.0464.950432.4037.0
5715.843554.77822.5297.321243.20818.2
62257.1371331.71141.0---
81558.298844.59845.84329.3323307.61023.6
9338.88887.43374.21306.109829.37936.5
10---2202.7361795.23018.5
berberine---857.387619.03327.8
Comparing the chemical structures of the six active alkaloids above, all the quaternary protoberberine alkaloids (berberine, palmatine and dehydrocorydaline) show strong aromatase binding activities (Figure 6a), indicating the importance of quaternary ammonium group in the interaction between the alkaloids and aromatase. When C-13 position of C ring is substituted by methyl group, the aromatase binding activity was slightly decrease (the decrease of peak area of palmatine is 5.1% higher than that of dehydrocorydaline, as shown in Figure 5). The potent binding might be the result of the participation of quaternary ammonium group in the hydrogen bonds interactions with the carboxylate oxygen atoms in protein residues. When comes to the tertiary protoberberine alkaloids, they also have aromatase binding activities. Comparing the structures of tetrahydrocolumbamine (peak 2), tetrahydropalmatine (peak 5) and corydaline (peak 9), it is demonstrated that the methoxyl group at C-2 position of A ring superseded by the hydroxyl group will decrease the aromatase binding activity, and the methyl group substituted at C-13 position of C ring will obviously increase the activity (Figure 6b). The other types of alkaloids such as the protopine analogs (protopine and allocryptopine) and the glaucine analogs (dehydroglaucine) possessed no aromatase binding activities in this study.
Molecules 15 03556 g006 550
Figure 6. The possible structure-binding activity relationships of the alkaloids from the dichloromethane extract of C. yanhusuo.
Figure 6. The possible structure-binding activity relationships of the alkaloids from the dichloromethane extract of C. yanhusuo.
Molecules 15 03556 g006

3. Experimental

3.1. Apparatus

Prep. HPLC: Agilent-1100 system; photodiode array detector; Zorbax-C18 column (250 × 21.2 mm, 7 μm, Agilent Technologies, USA). 1H- and 13C-NMR: Bruker Ultrashield Plus 500 MHz spectrometer. HPLC: Agilent 1100 HPLC system (Waldbronn, Germany) equipped with a Zorbax SB-C18 column (250 × 4.6 mm, 5 μm, Agilent Technologies, USA). ESI-MS: Thermo Finnigan LCQ Deca XPplus ESI ion trap mass spectrometer (San Jose, CA, USA) in positive ion mode. The MS operating parameters were as follows: collision gas, ultra-high-purity helium (He); nebulizing gas, high-purity nitrogen (N2); ion spray voltage, -4.5 kV; sheath gas (N2), 5 arbitrary units; capillary temperature, 275 °C; capillary voltage, -15 V; tube lens offset voltage, -30 V. The collision energy for collision-induced dissociation (CID) was between 30% and 45%, and the isolation width of precursor ions was 3.0 Th.

3.2. Material and reagents

The air-dried tubers of C. yanhusuo were collected in Pan’an, Zhejiang province, People’s Republic of China, in March 2008. The plant material was identified by the authors and a voucher specimen (No. 080401) had been deposited in the herbarium of the School of Pharmaceutical Sciences, Zhejiang University. Aromatase was purchased from BD Biosciences (San Jose, CA, USA). HPLC-grade methanol (Merck, Darmstadt, Germany) and formic acid (Tedia, Fairfield, OH, USA) were utilized for the HPLC analysis. Deionized water was purified using a Milli-Q system (Millipore, Bedford, MA, USA). All the other chemicals and solvents were of analytical-reagent grade. Nine reference compounds including tetrahydrocolumbamine, protopine, allocryptopine, berberine, tetrahydropalmatine, palmatine, corydaline, dehydrocorydaline and dehydroglaucine were isolated from the dichloromethane fraction of the 95% ethanol extract of C. yanhusuo. Their structures were elucidated by NMR spectroscopic analysis and comparison with the literature data. Purities of all the reference compounds were greater than 95% according to HPLC analysis.

3.3. HPLC conditions

HPLC analysis was performed on an Agilent 1100 HPLC instrument coupled to a binary pump, a diode array detector (DAD), an autosampler and a column thermostat. The sample was analyzed on a Zorbax SB-C18 column (250 × 4.6 mm, 5 μm, Agilent Technologies, USA). A linear gradient elution of A (10 mM ammonium acetate solution, pH was adjusted to 3.5 by formic acid) and B (methanol) was used according to the following profile: 0–40 min, 38% B; 40–55 min, 38-50% B; 55–65 min, 50–70% B and maintained 70% B during the next 10 min. The flow rate was 0.5 mL/min and the column temperature was set at 30 °C. The injection volume was 10 μL. The UV spectra were recorded from 190 to 400 nm.

3.4. Ultrafiltration LC-MS screening

Nine isolated reference alkaloids were mixed and dissolved in methanol as the reference compound stock solution (1 mM for each compound). The dichloromethane fraction of the 95% ethanol extract of C. yanhusuo was dissolved in methanol to obtain the extract stock solution (20 mg/mL). The extract stock solution and the reference compounds stock solution were incubated with 50 nM aromatase for 30 min at 37 °C in a total volume of 200 µL of deionized water (The final concentration of the extract stock solution and each reference compound were 2 mg/mL and 100 μM, respectively). After incubation, the solution was filtered though a Microcon (Millipore, Bedford, MA) YM-10 centrifugal filter containing a regenerated cellulose ultrafiltration membrane with a 10,000 MW cutoff by centrifugation at 12,000 g for 30 min at room temperature. The ultrafiltrate was transferred into HPLC vials and analyzed by LC-MS. For comparison, the two above mentioned sample solutions were prepared in an identical manner except for the use of aromatase. Naringenin was chosen as the positive control (The final concentration of naringenin in incubation solution was 100 μM).

4. Conclusions

In this paper, we identified nine alkaloids from the dichloromethane extract of C. yanhusuo and tested their aromatase binding activities using an ultrafiltration LC-MS screening method. The results showed that the quaternary protoberberine alkaloids and the tertiary protoberberine alkaloids had aromatase binding activities, while the protopine analogs and the glaucine analogs had no such activities. Based on the results of the study, the quaternary protoberberine alkaloids and the tertiary protoberberine alkaloids certainly merit continued and comparative pharmacological study for the future.

Supplementary Materials

Supplementary materials can be seen at https://www.mdpi.com/1420-3049/15/5/3556/S1.

Acknowledgements

This research work is financially supported by Analysis and Detection Foundation of Science and Technology Department of Zhejiang Province (No. 2008F017) and Excellent Young Teacher Project of Education Department of Zhejiang Province.

References

  1. Bulun, S.E.; Lin, Z.; Imir, G.; Amin, S.; Demura, M.; Yilmaz, B.; Martin, R.; Utsunomiya, H.; Thung, S.; Gurates, B.; Tamura, M.; Langoi, D.; Deb, S. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol. Rev. 2005, 57, 359–383. [Google Scholar] [CrossRef]
  2. Santen, R.J. Inhibition of aromatase: insights from recent studies. Steroids 2003, 68, 559–567. [Google Scholar] [CrossRef]
  3. Fisher, B.; Costantino, J.P.; Wickerham, D.L.; Redmond, C.K.; Kavanah, M.; Cronin, W.M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast caner: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998, 90, 1371–1388. [Google Scholar] [CrossRef]
  4. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005, 26, 331–345. [Google Scholar] [CrossRef]
  5. Evans, C.T.; Ledesma, D.B.; Schulz, T.Z.; Simpson, E.R.; Mendelson, C.R. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P450 mRNA. Proc. Natl. Acad. Sci. USA 1986, 83, 6387–6391. [Google Scholar] [CrossRef]
  6. Brueggemeier, R.W. Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 2006, 7, 1919–1930. [Google Scholar] [CrossRef]
  7. Kendall, A.; Dowsett, M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr. Relat. Cancer 2006, 13, 827–837. [Google Scholar] [CrossRef]
  8. Wong, Z.W.; Ellis, M.J. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Brit. J. Cancer 2004, 90, 20–25. [Google Scholar] [CrossRef]
  9. Milla-Santos, A.; Milla, L.; Portella, J.; Rallo, L.; Pons, M.; Rodes, E.; Casanovas, J.; Puig-Gali, M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am. J. Clin. Oncol. 2003, 26, 317–322. [Google Scholar]
  10. Arora, A.; Potter, J.F. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J. Am. Geriatr. Soc. 2004, 52, 611–616. [Google Scholar] [CrossRef]
  11. Goss, P.E. Risks versus benefits in the clinical application of aromatase inhibitors. Endocr. Relat. Cancer 1999, 6, 325–332. [Google Scholar] [CrossRef]
  12. Gnant, M. Management of bone loss induced by aromatase inhibitors. Cancer Invest. 2006, 24, 328–330. [Google Scholar] [CrossRef]
  13. Chlebowski, R.T.; Anderson, G.L.; Geller, M.; Col, N. Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. Clin. Breast Cancer 2006, 6, 58–64. [Google Scholar] [CrossRef]
  14. Lee, D.; Bhat, K.P.; Fong, H.H.; Farnsworth, N.R.; Pezzuto, J.M.; Kinghorn, A.D. Aromatase inhibitors from Broussonetia papyrifera. J. Nat. Prod. 2001, 64, 1286–1293. [Google Scholar] [CrossRef]
  15. Chen, S.; Cho, M.; Karlsberg, K.; Zhou, D.; Yuan, Y.C. Biochemical and biological characterization of a novel anti-aromatase coumarin derivative. J. Biol. Chem. 2004, 279, 48071–48078. [Google Scholar]
  16. Blanco, J.G.; Gil, R.R.; Alvarea, C.I.; Patrito, L.C.; Genti-Raimondi, S.; Flury, A. A novel activity for a group of sesquiterpene lactones: inhibition of aromatase. FEBS Lett. 1997, 409, 396–400. [Google Scholar] [CrossRef]
  17. Wang, Y.; Lee, K.W.; Chan, F.L.; Chen, S.; Leung, L.K. The red wine polyphenol reseratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol. Sci. 2006, 92, 71–77. [Google Scholar] [CrossRef]
  18. Kadohama, N.; Shintani, K.; Osawa, Y. Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase. Cancer Lett. 1993, 75, 175–182. [Google Scholar] [CrossRef]
  19. Ng, P.C.; Ho, D.D.; Ng, K.H.; Kong, Y.C.; Cheng, K.F.; Stone, G. Mixed estrogenic and anti-estrogenic activities of yuehchukene-a bis-indole alkaloid. Eur. J. Pharmacol. 1994, 264, 1–12. [Google Scholar] [CrossRef]
  20. Ding, B.; Zhou, T.; Fan, G.; Hong, Z.; Wu, Y. Qualitative and quantitative determination of ten alkaloids in traditional Chinese medicine Corydalis yanhusuo W.T. Wang by LC-MS/MS and LC-DAD. J. Pharm. Biomed. Anal. 2007, 45, 219–226. [Google Scholar] [CrossRef]
  21. Ma, Z.Z.; Xu, W.; Jensen, N.H.; Roth, B.L.; Liu-Chen, L.Y.; Lee, D.Y. Isoquinoline alkaloids isolated from Corydalis yanhusuo and their binding affinities at the dopamine D1 receptor. Molecules 2008, 13, 2303–2312. [Google Scholar] [CrossRef]
  22. Ou, J.; Kong, L.; Pan, C.; Su, X.; Lei, X.; Zou, H. Determination of DL-tetrahydropalmatine in Corydalis yanhusuo by L-tetrahydropalmatine imprinted monolithic column coupling with reversed-phase high performance liquid chromatography. J. Chromatogr. A 2006, 1117, 163–169. [Google Scholar] [CrossRef]
  23. Gao, J.L.; Shi, J.M.; He, K.; Zhang, Q.W.; Li, S.P.; Lee, S.M.; Wang, Y.T. Yanhusuo extract inhibits metastasis of breast cancer cells by modulating mitogen-activated protein kinase signaling pathways. Oncol. Rep. 2008, 20, 819–824. [Google Scholar]
  24. Nobuyuki, K.; Keiji, S.; Yoshio, O. Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase. Cancer Lett. 1993, 75, 175–182. [Google Scholar] [CrossRef]
  25. Grycova, L.; Dostal, J.; Marek, R. Quaternary protoberberine alkaloids. Phytochemistry 2007, 68, 150–175. [Google Scholar]
  26. Cutter, P.S.; Miller, R.B.; Schore, N.E. Synthesis of protoberberines using a silyl–directed Pictet-Spengler cyclization. Tetrahedron 2002, 58, 1471–1478. [Google Scholar] [CrossRef]
  27. Cushman, M.; Dekow, F.W. A total synthesis of corydaline. Tetrahedron 1978, 34, 1435–1439. [Google Scholar] [CrossRef]
  28. Wada, Y.; Kaga, H.; Uchiito, S.; Kumazawa, E.; Tomiki, M.; Onozaki, Y.; Kurono, N.; Tokuda, M.; Ohkuma, T.; Orito, K. On the synthesis of protopine alkaloids. J. Org. Chem. 2007, 72, 7301–7306. [Google Scholar] [CrossRef]
  29. Van Breemen, R.B.; Huang, C.R.; Nikolic, D.; Woodbury, C.P.; Zhao, Y.Z.; Venton, D.L. Pulsed ultrafiltration mass spectrometry: A new method for screening combinatorial libraries. Anal. Chem. 1997, 69, 2159–2164. [Google Scholar] [CrossRef]
  30. Zhao, Y.Z.; van Breemen, R.B.; Nikolic, D.; Huang, C.R.; Woodbury, C.P.; Schilling, A.; Venton, D.L. Screening solution-phase combinatorial libraries using pulsed ultrafiltration/electrospray mass spectrometry. J. Med. Chem. 1997, 40, 4006–4012. [Google Scholar] [CrossRef]
  31. Nikolic, D.; Habibi-Goudarzi, S.; Corley, D.G.; Gafner, S.; Pezzuto, J.M.; van Breemen, R.B. Evalution of cyclooxygenase-2 inhibitors using pulsed ultrafiltration mass spectrometry. Anal. Chem. 2000, 72, 3853–3859. [Google Scholar] [CrossRef]
  32. Liu, J.; Burdette, J.E.; Xu, H.; Gu, C.; van Breemen, R.B.; Bhat, K.P.L.; Booth, N.; Constantinou, A.I.; Pezzuto, J.M.; Fong, H.H.S.; Farnsworth, N.R.; Bolton, J.L. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food Chem. 2001, 49, 2472–2479. [Google Scholar]
  33. Sun, Y.; Gu, C.; Liu, X.; Liang, W.; Yao, P.; Bolton, J.L.; van Breemen, R.B. Ultrafiltration tandem mass spectrometry of estrogens for characterization of structure and affinity for human estrogen receptors. J. Am. Soc. Mass Spectrom. 2005, 16, 271–279. [Google Scholar] [CrossRef]
  34. Le Bail, J.C.; Laroche, T.; Marre-Fournier, F.; Habrioux, G. Aromatase and 17-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett. 1998, 133, 101–106. [Google Scholar] [CrossRef]
  35. Sanderson, J.T.; Hordijk, J.; Denison, M.S.; Springsteel, M.F.; Nantz, M.H.; van den Berg, M. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 2004, 82, 70–79. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of the nine reference compounds are available from the authors.

Share and Cite

MDPI and ACS Style

Shi, J.; Zhang, X.; Ma, Z.; Zhang, M.; Sun, F. Characterization of Aromatase Binding Agents from the Dichloromethane Extract of Corydalis yanhusuo Using Ultrafiltration and Liquid Chromatography Tandem Mass Spectrometry. Molecules 2010, 15, 3556-3566. https://doi.org/10.3390/molecules15053556

AMA Style

Shi J, Zhang X, Ma Z, Zhang M, Sun F. Characterization of Aromatase Binding Agents from the Dichloromethane Extract of Corydalis yanhusuo Using Ultrafiltration and Liquid Chromatography Tandem Mass Spectrometry. Molecules. 2010; 15(5):3556-3566. https://doi.org/10.3390/molecules15053556

Chicago/Turabian Style

Shi, Jing, Xiaoyu Zhang, Zhongjun Ma, Min Zhang, and Fang Sun. 2010. "Characterization of Aromatase Binding Agents from the Dichloromethane Extract of Corydalis yanhusuo Using Ultrafiltration and Liquid Chromatography Tandem Mass Spectrometry" Molecules 15, no. 5: 3556-3566. https://doi.org/10.3390/molecules15053556

Article Metrics

Back to TopTop